PEG-intron plus ribavirin in chronic hepatitis C patients refractory to prior treatment: end of follow-up report

McGarrity, Thomas J; Peiffer, Laurie P; Rhoades, Kathy; Chen, Steve T; Friedrich, Roland; McDonald, Thomas; Rosenberg, Dale; Bross, Ronald J; Smith, Mark A; Pickle, Harry
September 2003
American Journal of Gastroenterology;Sep2003 Supplement, Vol. 98, pS88
Academic Journal
An abstract of the article "PEG-intron Plus Ribavirin in Chronic Hepatitis C Patients Refractory to Prior Treatment: End of Follow-up Report," by Thomas J. McGarrity, Laurie P. Peiffer, and Kathy Rhoades is presented.


Related Articles

  • Review: Interferon-α plus ribavirin improves the virologic response in chronic hepatitis C. Reichen, Juerg // ACP Journal Club;Jul/Aug2002, Vol. 137 Issue 1, p17 

    Provides information on a study that examined whether interferon-α plus ribavirin more effective than interferon-α alone for improving hepatitis C virologic response and liver-related morbidity and mortality in patients with chronic hepatitis C. Data sources; Study selection; Main...

  • FDA Drug Approvals: Rebetol.  // Formulary;Sep2003, Vol. 38 Issue 9, p514 

    Reports on the approval of the ribavirin drug Rebetol from Schering-Plough, the first combination therapy for treatment of hepatitis C in children. Efficacy of the drug in trials; Requirement for dose modification; Dosage.

  • HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C. Romero-Gómez, Manuel; González-Escribano, María Francisca; Torres, Belén; Barroso, Natalia; Montes-Cano, Marco Antonio; Sánchez-Muñoz, Diego; Núñez-Roldan, Antonio; Aguilar-Reina, José // American Journal of Gastroenterology;Jul2003, Vol. 98 Issue 7, p1621 

    : ObjectiveThe aim of this study was to assess the influence of host genetic factors on response to combination therapy for chronic hepatitis C infection.: MethodsPatients with biopsy-proved chronic hepatitis C infection were treated with interferon alone (n = 143) or combined therapy of...

  • Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C. Siebert, U.; Sroczynski, G.; Rossol, S.; Wasem, J.; Ravens-Sieberer, U.; Kurth, B.M.; Manns, M.P.; McHutchison, J.G.; Wong, J.B. // Gut;Mar2003, Vol. 52 Issue 3, p425 

    Background: Peginterferon α-2b plus ribavirin therapy in previously untreated patients with chronic hepatitis C yields the highest sustained virological response rates of any treatment strategy but is expensive. Aims: To estimate the cost effectiveness of treatment with peginterferon α-2b...

  • Immunological markers predicting outcome in patients with hepatitis C treated with interferon-α and ribavirin. Lee, Silvia; Macquillan, Gerry C; Keane, Niamh M; Flexman, James; Jeffrey, Gary P; French, Martyn Ah; Brochier, Jean; Price, Patricia // Immunology & Cell Biology;Aug2002, Vol. 80 Issue 4, p391 

    Summary Type 1 (T1) cytokine responses are required for the clearance of hepatitis C virus by cytotoxic T lymphocytes, but can promote liver damage. Interferon-α (IFNα) can be expected to promote T1 cytokine responses, so treatment outcome may depend on the T1/T2 cytokine environment and...

  • Peginterferon-α-2a/ribavirin.  // Reactions Weekly;10/1/2011, Issue 1371, p30 

    The article describes the case of a 53-year-old man who developed bronchial cast expectoration while being treated with peginterferon-&alpha-2a and ribavirin for chronic hepatitis C.

  • A Randomized, Controlled Trial to Determine Whether Continued Ribavirin Monotherapy in Hepatitis C Virus--Infected Patients Who Responded to Interferon-Ribavirin Combination Therapy Will Enhance Sustained Virologic Response.  // Journal of Infectious Diseases;8/15/2001, Vol. 184 Issue 4, p405 

    This study assessed the use of ribavirin monotherapy to enhance sustained virologic response in hepatitis C virus (HCV)-infected patients who achieved virologic response to interferon (IFN)-ribavirin combination therapy. Patients who had chronic HCV infection and prior relapse were retreated...

  • Peginterferon-α-2b/ribavirin.  // Reactions Weekly;10/20/2012, Issue 1424, p40 

    The article describes the case of a 62-year-old man who developed branch retinal artery occlusion (BRAO) and central retinal vein occlusion (CRVO) during treatment with peginterferon-α-2b and ribavirin for chronic hepatitis C infection.

  • Filgrastim/peginterferon-α-2a/ribavirin.  // Reactions Weekly;1/29/2011, Issue 1336, p22 

    The article describes the case report of a 54-year-old female patient with chronic hepatitis C, and who developed severe recurrent neutropenia, thrombocytopenia and agranulocytosis during long-term therapy with SC peginterferon-α-2a combined with ribavirin.

  • Peginterferon/ribavirin.  // Reactions Weekly;11/13/2010, Issue 1327, p30 

    The article describes the case of depression and fatigue in two men while receiving treatment with peginterferon and ribavirin for chronic hepatitis C.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics